Format

Send to

Choose Destination
Front Psychiatry. 2013 May 7;4:26. doi: 10.3389/fpsyt.2013.00026. eCollection 2013.

Issues in the management of acute agitation: how much current guidelines consider safety?

Author information

1
Psychiatry Division, Department of Psychiatry, Neurobiology, Pharmacology and Biotechnology, University of Pisa Pisa, Italy.

Abstract

Agitated behavior constitutes up to 10% of emergency psychiatric interventions. Pharmacological tranquilization is often used as a valid treatment for agitation but a strong evidence base does not underpin it. Available literature shows different recommendations, supported by research data, theoretical considerations, or clinical experience. Rapid tranquilization (RT) is mainly based on parenteral drug treatment and the few existing guidelines on this topic, when suggesting the use of first generation antipsychotics and benzodiazepines, include drugs with questionable tolerability profile such as chlorpromazine, haloperidol, midazolam, and lorazepam. In order to systematically evaluate safety concerns related to the adoption of such guidelines, we reviewed them independently from principal diagnosis while examining tolerability data for suggested treatments. There is a growing evidence about safety profile of second generation antipsychotics for RT but further controlled studies providing definitive data in this area are urgently needed.

KEYWORDS:

parenteral treatment; psychomotor agitation; rapid tranquilization; respiratory depression; safety; tolerability; torsade de pointe; treatment guidelines

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center